Phosphorylation of the HuR ligand APRIL by casein kinase 2 regulates CD83 expression

被引:17
作者
Chemnitz, Jan [1 ]
Pieper, Dorothea [1 ]
Gruettner, Cordula [1 ]
Hauber, Joachim [1 ]
机构
[1] Heinrich Pette Inst Expt Virol & Immunol, Dept Cell Biol & Virol, D-20251 Hamburg, Germany
关键词
APRIL; Casein kinase 2; CD83; HuR; Leukocytes; T-CELL STIMULATION; MESSENGER-RNA EXPORT; DENDRITIC CELLS; NUCLEAR EXPORT; SOLUBLE CD83; B-LYMPHOCYTES; PROTEIN; CK2; MATURATION; TRANSCRIPTION;
D O I
10.1002/eji.200838619
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fully mature DC and, to a lesser extent, activated T and B cells express CD83, a surface molecule that appears to fulfil an important role in efficient T-cell activation. Recently, it has been shown that CD83 mRNA is transported from the nucleus to the cytoplasm by an uncommon route, involving the cellular RNA-binding protein HuR and the nuclear export receptor CRM1. Moreover, the shuttle phosphoprotein APRIL (ANP32B) has been shown to be required for HuR-mediated nucleocytoplasmic translocation of the CD83 mRNA by acting as an adaptor that links HuR and CRM1. Here, we are able to report that casein kinase 2 (CK2) phosphorylates APRIL on residue threonine244 (Thr(244)) and demonstrate that the CK2-specific inhibitor 4,5,6,7-tetrabromo-2-azabenzimidazole abolishes CD83 expression in activated Jurkat T cells by interfering with the nucleocytoplasmic translocation of CD83 mRNA. Depletion and knockdown studies demonstrate that the CK2 alpha' subunit is necessary for this regulation, whereas the CK2 a subunit seems to be dispensable. Taken together, the data presented significantly extend our knowledge of the complex regulation of CD83 mRNA processing and provides a novel strategy to interfere with CD83 expression.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 67 条
[1]   Targeting CK2 for cancer therapy [J].
Ahmad, KA ;
Wang, GX ;
Slaton, J ;
Unger, G ;
Ahmed, K .
ANTI-CANCER DRUGS, 2005, 16 (10) :1037-1043
[2]   Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor [J].
Aricha, Revital ;
Feferman, Tali ;
Souroujon, Miriam C. ;
Fuchs, Sara .
FASEB JOURNAL, 2006, 20 (02) :374-376
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Protein ligands to HuR modulate its interaction with target mRNAs in vivo [J].
Brennan, CM ;
Gallouzi, IE ;
Steitz, JA .
JOURNAL OF CELL BIOLOGY, 2000, 151 (01) :1-13
[6]   HuR and mRNA stability [J].
Brennan, CM ;
Steitz, JA .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (02) :266-277
[7]   Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis [J].
Channavajhala, P ;
Seldin, DC .
ONCOGENE, 2002, 21 (34) :5280-5288
[8]   Transport of messenger RNA from the nucleus to the cytoplasm [J].
Cole, Charles N. ;
Scarcelli, John J. .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (03) :299-306
[9]   Nuclear RNA export [J].
Cullen, BR .
JOURNAL OF CELL SCIENCE, 2003, 116 (04) :587-597
[10]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105